Price
No data yet.
Social Signal Score
Revenue
$55.80M+52.97%Company Profile
- CEO
- Jiang Pengfei
- Sector
- Consumer Cyclical
- Industry
- Apparel - Manufacturers
- Employees
- 24
- Beta
- -2.87
- Country
- HK
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 1.66
Financials
Revenue
$55.80M+53.0%Net Income
$-9.11MEBITDA
$-8.25MFree Cash Flow
$-45.08M-15909.1%EPS (diluted)
$-37.60Shares Outstanding (diluted)
241.7K+329.7%Operating Expenses
$30.80MCash & Debt
$10.09MReturn of Capital
$0.00Revenue by Segment (annual)
$672.69MDividend per Share
$0.05Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $137.25M | $331.7K | $5.20 |
| 2024 | $235.67M | $8.06M | $25.60 |
| 2023 | $174.20M | $4.41M | $14.08 |
| 2022 | $347.45M | $12.40M | $39.68 |
| 2021 | $240.54M | $5.45M | $17.28 |
| 2020 | $182.58M | $-3.33M | $-14.08 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $7.67
- Implied price
- $138.15
- Return from $4.02
- 102.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $68.68 — today's price is already 94.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 69.7% | 77.5% | 84.1% | 89.9% | 95.0% |
| 3.0% | 78.4% | 86.6% | 93.5% | 99.5% | 104.9% |
| 8.0% | 87.1% | 95.6% | 102.9% | 109.2% | 114.9% |
| 13.0% | 95.7% | 104.7% | 112.3% | 118.9% | 124.8% |
| 18.0% | 104.4% | 113.7% | 121.7% | 128.6% | 134.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (9)
- Newsglobenewswire.com·2d ago·Neutral
…3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclin…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for ratio…
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Neo-Concept International Announces Share Consolidation HONG KONG, Nov. 02, 2026 (GLOBE NEWSWIRE) -- On October 29, 2026, Neo-Concept International Group Holdings Ltd (the “Company”) held the Company's Extraordinary General Meeting (the “EGM”) , amongst which a share consolidation (the “Share Consolidation”) was approved by the shareholders, whereby every two (2) to every four hundred (400) issued and unissued shares (namely, both class A ordinary shares of par value US$0.0025 each and class B o
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tr…
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27…
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previous…
View source ↗ - Newsprnewswire.com·34d ago·Negative
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
…s Ltd Announces Pricing of $2.0 Million Registered Direct Offering HONGKONG, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Ltd (NASDAQ: NCI) (“Neo-Concept” or the “Company”), a one-stop apparel solution services provider, today announced that it has entered into securities purchase agreements with certain institutional investor for the purchase and sale of 2,000,000 of the Company's Class A ordinary shares (the “Class A ordinary shares”) (or pre-funded warrants in l…
View source ↗
Insider trading
Open-market buys and sells by NCI officers and directors.
- Bought
- —
- Sold
- $5.1m
0 trades
7 trades
- Howard Juliesold
- Howard Juliesold
- Howard Juliesold
- Howard Juliesold
- Howard Juliesold
- James Stephan Asold
- James Stephan Asold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NCI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
